179 related articles for article (PubMed ID: 20079362)
1. MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Paquette MA; Anderson AM; Lewis JR; Meshul CK; Johnson SW; Paul Berger S
Neuropharmacology; 2010 Jun; 58(7):1002-8. PubMed ID: 20079362
[TBL] [Abstract][Full Text] [Related]
2. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Dupre KB; Eskow KL; Steiniger A; Klioueva A; Negron GE; Lormand L; Park JY; Bishop C
Psychopharmacology (Berl); 2008 Jul; 199(1):99-108. PubMed ID: 18545986
[TBL] [Abstract][Full Text] [Related]
3. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Paquette MA; Martinez AA; Macheda T; Meshul CK; Johnson SW; Berger SP; Giuffrida A
Eur J Neurosci; 2012 Nov; 36(9):3224-34. PubMed ID: 22861201
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.
Flores AJ; Bartlett MJ; So LY; Laude ND; Parent KL; Heien ML; Sherman SJ; Falk T
Neurosci Lett; 2014 Apr; 564():48-52. PubMed ID: 24525249
[TBL] [Abstract][Full Text] [Related]
5. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Flores AJ; Bartlett MJ; Root BK; Parent KL; Heien ML; Porreca F; Polt R; Sherman SJ; Falk T
Neuropharmacology; 2018 Oct; 141():260-271. PubMed ID: 30201210
[TBL] [Abstract][Full Text] [Related]
6. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Mela F; Millan MJ; Brocco M; Morari M
Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
[TBL] [Abstract][Full Text] [Related]
7. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
[TBL] [Abstract][Full Text] [Related]
8. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
9. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
10. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
11. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
13. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Buck K; Ferger B
Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
[TBL] [Abstract][Full Text] [Related]
14. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
[TBL] [Abstract][Full Text] [Related]
15. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
16. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Bishop C; Krolewski DM; Eskow KL; Barnum CJ; Dupre KB; Deak T; Walker PD
J Neurosci Res; 2009 May; 87(7):1645-58. PubMed ID: 19115412
[TBL] [Abstract][Full Text] [Related]
18. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Arakawa K; Yuge N; Maehara S
Pharmacol Rep; 2020 Apr; 72(2):443-448. PubMed ID: 32144743
[TBL] [Abstract][Full Text] [Related]
19. Effect of the selective 5-HT
Frouni I; Kwan C; Bédard D; Belliveau S; Bourgeois-Cayer É; Gaudette F; Beaudry F; Hamadjida A; Huot P
Exp Brain Res; 2019 Jan; 237(1):29-36. PubMed ID: 30298296
[TBL] [Abstract][Full Text] [Related]
20. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]